Literature DB >> 12133938

CD40 ligand and CTLA-4 are reciprocally regulated in the Th1 cell proliferative response sustained by CD8(+) dendritic cells.

Francesca Fallarino1, Ursula Grohmann, Carmine Vacca, Roberta Bianchi, Maria C Fioretti, Paolo Puccetti.   

Abstract

Subsets of murine dendritic cells (DCs) from the spleen differ in their ability to induce proliferative responses in both primary and secondary CD4(+) T cells. Recent evidence indicates that lymphoid-related CD8(+) DCs fail to provide appropriate signals to freshly isolated secondary CD4(+) T cells to sustain their proliferation in vitro. In the present study, we examined peptide-pulsed CD8(-) and CD8(+) DCs for ability to stimulate Th1 and Th2 cell clones with the same Ag specificity. Defective ability to induce proliferation was selectively shown by CD8(+) DCs presenting Ag to the Th1 clone. The deficiency in CD8(+) DCs was overcome by CD40 triggering before peptide pulsing. When exposed to CD8(+) DCs in the absence of CD40 activation, the Th1 clone expressed low levels of CD40 ligand and high levels of surface CTLA-4. Neutralization of CTLA-4 during the DC/T cell coculture resulted in increased CD40 ligand expression and proliferation of T cells. Remarkably, the activation of CD40 on DCs under conditions that would increase Th1 cell proliferation, also resulted in down-regulation of surface CTLA-4. These results confirm differential effects of CD8(+) and CD8(-) DCs in the stimulation of Ag-primed Th cells. In addition, they suggest that reciprocal regulation of CD40 ligand and CTLA-4 expression occurs in Th1 cells exposed to CD8(+) DCs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133938     DOI: 10.4049/jimmunol.169.3.1182

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation.

Authors:  Ursula Hainz; Petra Obexer; Christiana Winkler; Peter Sedlmayr; Osamu Takikawa; Hildegard Greinix; Anita Lawitschka; Ulrike Pötschger; Dietmar Fuchs; Stephan Ladisch; Andreas Heitger
Journal:  Blood       Date:  2005-01-27       Impact factor: 22.113

2.  The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children.

Authors:  C-O Jonson; M Hedman; M Karlsson Faresjö; R Casas; J Ilonen; J Ludvigsson; O Vaarala
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  CD8alpha dendritic cells and immune protection from experimental allergic encephalomyelitis.

Authors:  A Pettersson; X-C Wu; C Ciumas; H Lian; V Chirsky; Y-M Huang; B Bjelke; H Link; B-G Xiao
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

4.  Modulation of the pulmonary type 2 T-cell response to Cryptococcus neoformans by intratracheal delivery of a tumor necrosis factor alpha-expressing adenoviral vector.

Authors:  Jami E Milam; Amy C Herring-Palmer; Raj Pandrangi; Roderick A McDonald; Gary B Huffnagle; Galen B Toews
Journal:  Infect Immun       Date:  2007-07-23       Impact factor: 3.441

Review 5.  Cardiac phenotype in mouse models of systemic autoimmunity.

Authors:  Chandan Sanghera; Lok Man Wong; Mona Panahi; Amalia Sintou; Muneer Hasham; Susanne Sattler
Journal:  Dis Model Mech       Date:  2019-03-08       Impact factor: 5.758

6.  Anti-CD40 predominates over anti-CTLA-4 to provide enhanced antitumor response of DC-CIK cells in renal cell carcinoma.

Authors:  Ying Zhang; Xiaolong Wu; Amit Sharma; Hans Weiher; Matthias Schmid; Glen Kristiansen; Ingo G H Schmidt-Wolf
Journal:  Front Immunol       Date:  2022-08-25       Impact factor: 8.786

Review 7.  Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.

Authors:  Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-03-07       Impact factor: 46.802

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.